The economics of therapy of gastroesophageal reflux disease

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Gastroesophageal Reflux Disease (GERD) is a frequent and morbid clinical condition with a profound impact on quality of life. Treating patients with complicated GERD with H2RAs is clinically and economically inappropriate. Although drug acquisition costs are greater with PPIs compared with H2RAs (or surgical therapy compared with H2RAs) the greater efficacy of PPIs or surgery make them more cost-effective both in short-term and long-term economic models. The therapy which maintains the patient in remission is the cost-effective approach to managing the patient with GERD.

Original languageEnglish (US)
Pages (from-to)126-130
Number of pages5
JournalGastroenterology International
Volume10
Issue number3
StatePublished - 1997

Fingerprint

Gastroesophageal Reflux
Economics
Economic Models
Costs and Cost Analysis
Drug Costs
Therapeutics
Quality of Life

Keywords

  • Chest pain
  • Gastroesophageal reflux
  • Rumination

ASJC Scopus subject areas

  • Gastroenterology

Cite this

The economics of therapy of gastroesophageal reflux disease. / Fennerty, M (Brian).

In: Gastroenterology International, Vol. 10, No. 3, 1997, p. 126-130.

Research output: Contribution to journalArticle

@article{81e39d198b264e018e2a9d162890f4b5,
title = "The economics of therapy of gastroesophageal reflux disease",
abstract = "Gastroesophageal Reflux Disease (GERD) is a frequent and morbid clinical condition with a profound impact on quality of life. Treating patients with complicated GERD with H2RAs is clinically and economically inappropriate. Although drug acquisition costs are greater with PPIs compared with H2RAs (or surgical therapy compared with H2RAs) the greater efficacy of PPIs or surgery make them more cost-effective both in short-term and long-term economic models. The therapy which maintains the patient in remission is the cost-effective approach to managing the patient with GERD.",
keywords = "Chest pain, Gastroesophageal reflux, Rumination",
author = "Fennerty, {M (Brian)}",
year = "1997",
language = "English (US)",
volume = "10",
pages = "126--130",
journal = "Gastroenterology International",
issn = "0950-5911",
publisher = "International Universities Press Inc.",
number = "3",

}

TY - JOUR

T1 - The economics of therapy of gastroesophageal reflux disease

AU - Fennerty, M (Brian)

PY - 1997

Y1 - 1997

N2 - Gastroesophageal Reflux Disease (GERD) is a frequent and morbid clinical condition with a profound impact on quality of life. Treating patients with complicated GERD with H2RAs is clinically and economically inappropriate. Although drug acquisition costs are greater with PPIs compared with H2RAs (or surgical therapy compared with H2RAs) the greater efficacy of PPIs or surgery make them more cost-effective both in short-term and long-term economic models. The therapy which maintains the patient in remission is the cost-effective approach to managing the patient with GERD.

AB - Gastroesophageal Reflux Disease (GERD) is a frequent and morbid clinical condition with a profound impact on quality of life. Treating patients with complicated GERD with H2RAs is clinically and economically inappropriate. Although drug acquisition costs are greater with PPIs compared with H2RAs (or surgical therapy compared with H2RAs) the greater efficacy of PPIs or surgery make them more cost-effective both in short-term and long-term economic models. The therapy which maintains the patient in remission is the cost-effective approach to managing the patient with GERD.

KW - Chest pain

KW - Gastroesophageal reflux

KW - Rumination

UR - http://www.scopus.com/inward/record.url?scp=0031464934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031464934&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 126

EP - 130

JO - Gastroenterology International

JF - Gastroenterology International

SN - 0950-5911

IS - 3

ER -